Ligand partner SQ Innovation receives approval from FDA for Lasix ONYU

Ligand (LGND) Pharmaceuticals announced that its partner SQ Innovation has received approval from the U.S. Food and Drug Administration, FDA, for Lasix ONYU, a novel drug-device combination for the treatment of edema in adult patients with chronic heart failure. Lasix ONYU can be administered subcutaneously outside the healthcare setting for selected patients, as prescribed by a clinician, without the need for a healthcare professional to administer the drug. “Lasix ONYU has the potential to benefit millions of heart failure patients who would otherwise receive treatment with IV diuretics in the hospital,” said Todd Davis, CEO of Ligand. “Our partnership with SQ Innovation further demonstrates the powerful role Captisol plays in the development and delivery of new medicines. By optimizing drug solubility, stability, and bioavailability, we are paving the way for companies to develop safer and more effective therapies that can change patient lives for the better.”